Format

Send to

Choose Destination
Jpn J Radiol. 2019 May 17. doi: 10.1007/s11604-019-00843-1. [Epub ahead of print]

Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Author information

1
Department of Gastroenterology, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305-8575, Japan. k-fukuda@md.tsukuba.ac.jp.
2
Department of Radiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
3
Department of Gastroenterology, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305-8575, Japan.
4
Department of Radiology, Tsukuba Medical Center Hospital, Ibaraki, Japan.

Abstract

PURPOSE:

In radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), it is difficult to assess the ablative margin (AM) precisely by comparing pre- and post-RFA CT images. We prospectively studied the AMs using magnetic resonance imaging (MRI) with pre-administered superparamagnetic iron oxide (SPIO). SPIO is safe for kidney disease patients.

MATERIALS AND METHODS:

Hepatocellular carcinoma patients were treated with RFA within 8 h of SPIO administration. On T2*-weighted MRI performed 4-7 days later, AM was visualized as a hypointense rim. The ablation status was classified as AM(+) if the rim completely surrounded the tumor, AM(0) if the rim was partly discontinuous without tumor protrusion, and AM(-) if the rim was partly discontinuous with tumor protrusion. The minimal thickness of AM was measured. AM(-) tumors were re-treated consecutively.

RESULTS:

In total, 85 HCCs ablated in 76 patients were evaluated. The local recurrence rate at 3 years was 2% for AM(+) tumors and 34% for AM(0) tumors (p < 0.01). In addition, no local recurrence was seen in the tumors with an AM of ≥ 2 mm.

CONCLUSION:

MRI with pre-administered SPIO is useful for determining the AM precisely, and an AM of ≥ 2 mm is recommended for curative RFA.

TRIAL REGISTRATION NUMBER:

This study was registered with UMIN Clinical Trials Registry (UMIN 000025406).

KEYWORDS:

Ablative margin; Hepatocellular carcinoma; Radiofrequency ablation; Superparamagnetic iron oxide

PMID:
31102138
DOI:
10.1007/s11604-019-00843-1

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center